Avomeen & Daré Bioscience Form Strategic Partnership to Accelerate Novel Pipeline

Avomeen and Daré Bioscience, Inc. recently announced the companies have signed an agreement under which Avomeen will provide contract product development laboratory services with a team specifically assembled to support the advancement of Daré’s innovative pipeline of investigational products designed to address persistent unmet needs in women’s health.  The unique partnership model is intended to enable Daré to leverage Avomeen’s scientific expertise, including advanced instrumentation and development techniques, and accelerate development of key programs in a capital-efficient manner.

Daré and Avomeen are currently collaborating on development-stage programs, including Ovaprene, an investigational hormone-free, monthly contraceptive, and intend to expand their partnership to include more programs in Daré’s women’s health pipeline. Central to the collaboration is Avomeen’s ability to develop customized protocols, test methods, and formulations with processes tailored to unique product requirements and specifications. This capability aligns with Daré’s portfolio of potential first-in-category products, which often require a customized approach to method development.

“One of the clear goals of this partnership is to leverage Avomeen’s ingenuity and expertise in biopharmaceutical development to support our clinical program initiatives in women’s health,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Avomeen has a proven track record and impressive regulatory accreditations combined with cutting-edge technological capabilities that we believe will enable us to accelerate development activities across our portfolio.  Further, we believe that the partnership agreement will result in greater efficiencies and savings in our research and development expenditures.”

Under the terms of the agreement, Avomeen will be Daré’s preferred provider of product development laboratory services for an initial three-year period, provided that Avomeen has the expertise, resources and availability to perform the services that Daré requires. In exchange for receiving that exclusive service provider status, Avomeen will assemble operating and oversight teams committed to the partnership and provide a preferred discounted pricing structure and, if volume reaches designated levels, will also provide scientific personnel dedicated exclusively to supporting Daré’s development programs covered by the agreement.

“Avomeen is excited about this partnership and is well positioned to augment the existing clinical technical and regulatory competencies at Daré,” added Mark Harvill, CEO of Avomeen. “We have been able to apply our novel scientific and technical solutions to Daré’s diverse portfolio, in large part due to the collaborative approach that Daré implements with its development partners like Avomeen.”

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Daré’s clinical-stage product portfolio includes potential first-in-category candidates in clinical development: Ovaprene, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause.  For more information, visit www.darebioscience.com.

Avomeen is an accredited, independent contract research organization (CRO) and contract development and manufacturing organization (CDMO), bringing chemists and scientists together to tackle scientific product-development challenges in the biopharmaceutical industry and  across other industries and applications. The company’s unique approach is singularly focused on applying its expertise and working closely with clients to help transform their biggest goals into real solutions. Throughout each step of product development, Avomeen’s scientists and experts work within a rigorous quality system to ensure products comply with regulatory requirements and consumer expectations. Avomeen’s facility is FDA-Registered and DEA-Licensed (schedules 1-5), and its laboratories are also GLP/GMP-compliant, ISO 17025 accredited, and QP authorized for clinical trial material in the EU. Avomeen offers complete, comprehensive scientific solutions that support the entire product development lifecycle, with a focus on growing strategic partnerships. For more information, visit www.avomeen.com.